ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > Cell > uPAR > CHEK-ATP151

HEK293/Human uPAR Stable Cell Line

  • Description
    The HEK293/Human uPAR Stable Cell Line was engineered to express the receptor full length human uPAR (Gene ID: 5329), used to mimic cancer target cells. Surface expression of human uPAR was confirmed by flow cytometry.
  • Application

    • Useful for cell-based uPAR binding assay

  • Growth Properties
    Adherent
  • Selection Marker
    Puromycin (2 μg/mL)
  • Culture Medium
    DMEM + 10% FBS
  • Freeze Medium
    Serum-free cell cryopreservation medium
  • Quantity
    1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
  • Storage
    Frozen in liquid nitrogen.
  • Mycoplasma Testing
    Negative
  • Sterility Testing
    Negative
  • Instructions for Use
    See data sheet for detailed culturing and assay protocol.
Bioactivity
 uPAR FACS

Expression analysis of human uPAR on HEK293/Human uPAR Stable Cell Line by FACS.
Cell surface staining was performed on HEK293/Human uPAR Stable Cell Line or negative control cell using PE-labeled anti-human uPAR antibody.

Please contact us if you are interested in related cell pool service.

  • Background
    Urokinase plasminogen activator surface receptor (U-PAR) is also known as PLAUR, Monocyte activation antigen Mo3, CD antigen CD87. PLAUR contains three UPAR/Ly6 domains. U-PAR is expressed in neurons of the rolandic area of the brain (at protein level) and is also expressed in the brain. PLAUR / CD87 interacts with MRC2, SRPX2 and SORL1. PLAUR / UPAR acts as a receptor for urokinase plasminogen activator and plays a role in localizing and promoting plasmin formation. U-PAR mediates the proteolysis-independent signal transduction activation effects of U-PA.
  • License Disclosure
    This cell line is provided for research use only. This license does not permit you to share, distribute, sell, sublicense, or otherwise make this cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. The license does not permit modification of this cell line in any way. Inappropriate use or distribution of this cell line will result in revocation of the license. Modifications of this cell line, transfer to another facility, or commercial use of the cell lines may require a separate license and additional fees. AcroBiosystems does not warrant the suitability of this cell line for any particular use, and does not accept any liability in connection with the handling or use of this cell line.
  • Clinical and Translational Updates

コメント (0)


ETD of in-stock products: 4 business days

価格(JPY) : 980,000

プロモーション&展示



医薬品開発状況

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:5 Details
  • Latest Research Phase:Phase 2 Clinical

データシート&ドキュメンテーション

関連製品一覧

新製品

お問い合わせ&コメント

This web search service is supported by Google Inc.

totopphone